Headache severity recorded on a three scale,
Conditions
Interventions
cinnarizine (37.5 mg/day in children aged 6–12 years and 50 mg/day in children aged 12–17 years,propranolol (1-
mg/kg/day)
Experimental Drug,Active Comparator Drug
cinnarizine,propranolol
Sponsors
Hormozgan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Years to 14 Years
Inclusion criteria
Inclusion criteria: Children aged 6-14 years who had migraine with and without aura, defined by the International International Headache Society criteria for migraine (17), were enrolled into the study. All patients experienced one or more headaches per week for at least 6 months or had severe disabling or intolerable headache before entry into the study.
Exclusion criteria
Exclusion criteria: children who had complicated migraine that required medications other than analgesics, past treatment with migraine prophylactic agent, persistent increasing headache, comorbid conditions such as seizures, abnormal neuroimaging, history of epilepsy, and history of contraindications to cinnarizine or propranolol administration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| compare the efficacy of cinnarizine with propranolol in the prophylaxis of pediatric migraine headac 2-month follow-up The frequency, severity of headaches | — |
Secondary
| Measure | Time frame |
|---|---|
| N/A - N/A | — |
Countries
Iran
Contacts
Public ContactAli Reza Moayedi
Hormozgan University of Medical Sciences
Outcome results
None listed